Health
New STRENGTH Analysis Reignites Debate on Omega-3 CV Benefits – Medscape
The new analysis showing no benefits linked to higher achieved levels of EPA casts doubt over the use of high-dose omega-3 fatty acid products for preventing cardiovascular…
Questions over the cardiovascular benefits shown in the REDUCE-IT trial with icosapent ethyl, a high-dose eicosapentaenoic acid (EPA) product, have been reignited with a new analysis from the STRENGTH trial showing no benefit of a high-dose combined omega-3 fatty acid product in patients who achieved the highest EPA levels and no harm in those with the highest levels of docosahexaenoic acid (DHA).
STRENGTH investigator Steven Nissen, MD, said these new results add to concerns about the positive…
-
Noosa News6 hours agoMan charged over allegedly abandoning Arnie the German shepherd in car after claiming dog and vehicle were stolen
-
Noosa News7 hours agoMotorcyclist dies in crash with truck
-
Noosa News21 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
General21 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate